Skip to main content
SpringerLink
Log in

The Evaluation of Beat Blocker and Calcium Antagonist Drugs

  • Book
  • © 1982

Overview

Editors:
  1. Joel Morganroth

    1. The Lankenau Medical Research Center, Jefferson Medical College of The Thomas Jefferson University, Philadelphia, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. E. Neil Moore

    1. School of Veterinary Medicine, University of Pennsylvania, Philadelphia, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Developments in Cardiovascular Medicine (DICM, volume 18)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (33 chapters)

  1. Front Matter

    Pages I-IX
    Download chapter PDF

  2. Introduction

    • Joel Morganroth
    Pages 1-6

  3. Beta-Adrenoceptor Blocking Agents: Historical Perspectives

    • William B. Abrams
    Pages 7-20

  4. The Clinical Relevance of Beta-Receptor Blockade, Intrinsic Sympathomimetic Activity and Membrane Depressant Action

    • P. Somani
    Pages 21-40

  5. Pharmacokinetics and Pharmacodynamics of Beta-Blockers

    • Alastair J. J. Wood
    Pages 41-61

  6. Importance of Alpha Blocking and Vasodilator Effects of Beta Blocking Agents

    • Jay N. Cohn
    Pages 63-71

  7. Are Animal Models Useful in Determining if All Beta-Blocking Agents are the Same?

    • E. Neil Moore, Joseph F. Spear
    Pages 73-85

  8. Moderator’s Comments on Beta Blocking Drugs

    • D. C. Harrison
    Pages 87-88

  9. General Group Discussion — are All Beta-Blocking Agents the Same?

    • Donald Harrison
    Pages 89-107

  10. How to Define Beta-Blocker Usefulness in Hypertension: Is Ambulatory Monitoring Necessary?

    • Norman M. Kaplan
    Pages 109-124

  11. Evaluation of Beta Blocking Agents in the Treatment of Angina Pectoris Due to Coronary Artery Disease

    • Stephen E. Epstein
    Pages 125-128

  12. Beta Blocking Agents in the Treatment of Ventricular Arrhythmias

    • Joel Morganroth
    Pages 129-140

  13. How to Define Beta Blocker Usefulness in Supraventricular Arrhythmias.

    • E. Rowland, D. M. Krikler
    Pages 141-149

  14. How to Define Beta-Blocker Usefulness in Hypertension, Angina and Arrhythmias: An Overview

    • Eric L. Michelson
    Pages 151-156

  15. General Group Discussion — How to Define Beta-Blocker Usefulness In:

    • Eric Michelson
    Pages 157-182

  16. Comparative Safety of Beta Blocking Drugs

    • D. C. Harrison
    Pages 183-188

  17. Current Problems in the Evaluation of New Beta-Blocking Agents

    • Robert Temple
    Pages 189-196

  18. General Group Discussion — Problems in Study Design

    • Joel Morganroth
    Pages 197-215

  19. Remarks

    • Arthur Hull Hayes Jr.
    Pages 217-230

  20. Beta Blocker in Sudden Death Prevention

    • James A. Schoenberger
    Pages 231-232
Back to top

Keywords

About this book

With the beginning of the 1980's it was becoming increasingly evident that the lack of approval of new cardiovascular agents for use by clinicians in the United States for the treatment of cardiovascular disorders was becoming a problem. Patients requiring medical therapy for hypertension, angina pectoris, arrhythmias, congestive heart failure, and vasospastic disorders of the coronary arteries could receive in the United States only a small number of the drugs available to physicians in the rest of the world. In fact, as the 1980's began, there was only one available beta blocking agent released by The Food and Drug Administration; and even as of this writing, no oral calcium antagonist agent. This lag, in part, has been due to the confusion of proper and expeditious methods to define safety and efficacy of such agents so that the United States regulatory agency (Food and Drug Administration) could approve the use of such agents by clinicians. The vast number of new beta blocker and calcium antagonist agents being developed, as well as the long-term use abroad of many new drugs, has raised important questions as to how relative safety and efficacy of such agents can be determined to facilitate availability in the United States.

Editors and Affiliations

  • The Lankenau Medical Research Center, Jefferson Medical College of The Thomas Jefferson University, Philadelphia, USA

    Joel Morganroth

  • School of Veterinary Medicine, University of Pennsylvania, Philadelphia, USA

    E. Neil Moore

Bibliographic Information

  • Book Title: The Evaluation of Beat Blocker and Calcium Antagonist Drugs

  • Editors: Joel Morganroth, E. Neil Moore

  • Series Title: Developments in Cardiovascular Medicine

  • DOI: https://doi.org/10.1007/978-94-009-7561-3

  • Publisher: Springer Dordrecht

  • eBook Packages: Springer Book Archive

  • Copyright Information: Martinus Nijhoff Publishers, The Hague 1982

  • Hardcover ISBN: 978-90-247-2642-4Due: 28 February 1982

  • Softcover ISBN: 978-94-009-7563-7Published: 02 November 2011

  • eBook ISBN: 978-94-009-7561-3Published: 06 December 2012

  • Series ISSN: 0166-9842

  • Edition Number: 1

  • Number of Pages: 419

  • Topics: Cardiology

Publish with us

Policies and ethics

Back to top

Search

Navigation